Home › Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program
 

Keywords :   


Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program

2014-07-30 10:52:33| drugdiscoveryonline Home Page

Humacyte, Inc., a pioneer in regenerative medicine, has announced that the U.S. Food and Drug Administration (FDA) has designated the HumaGraft development program for vascular access in hemodialysis patients as a Fast Track Development Program

Tags: program access fast track

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
17.05Eastern North Pacific Tropical Weather Outlook
17.05Boeing boss's $33m pay package approved
17.05Heifers and female cows remain hot topic at sale barn
17.05Dutch Boy Paints Introduces Professional Series at Menards
17.05Atlantic Tropical Weather Outlook
More »